Piceatannol-3′-O-β-D-glucopyranoside inhibits neuroexcitotoxicity and ferroptosis through NMDAR/NRF2/BACH1/ACSL4 pathway in acute ischemic stroke

Neuronal protection is a well-established method of acute ischemic stroke (AIS) treatment. The pharmacodynamic effect of Piceatannol-3′-O-β-D-glucopyranoside (Chinese name: Hartigan, QZZG) on AIS has been reported, but the molecular mechanism of this effect remains unknown. The purpose of this study...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Free radical biology & medicine 2025-02, Vol.227, p.667-679
Hauptverfasser: Fan, Genhao, Liu, Jia, Liu, Menglin, Huang, Yuhong
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 679
container_issue
container_start_page 667
container_title Free radical biology & medicine
container_volume 227
creator Fan, Genhao
Liu, Jia
Liu, Menglin
Huang, Yuhong
description Neuronal protection is a well-established method of acute ischemic stroke (AIS) treatment. The pharmacodynamic effect of Piceatannol-3′-O-β-D-glucopyranoside (Chinese name: Hartigan, QZZG) on AIS has been reported, but the molecular mechanism of this effect remains unknown. The purpose of this study is to elucidate the pharmacodynamic effects and mechanisms of QZZG in the treatment of AIS. A combined network pharmacology and metabolomics approach was used to predict the key targets and pathways of QZZG in the treatment of AIS and to elucidate the mechanism of QZZG through experimental validation. In this study, QZZG improved histopathologic features and reduced infarct volume and neurologic deficit scores. Integrated network pharmacology and metabolomics revealed that QZZG may protect neurons by regulating glutamate and its receptors, and that glutamate is closely related to NMDAR1, NRF2, and Caspase-3. Pathway analysis results suggested that NMDAR-mediated Ca2+ inward flow is one of the critical pathways. In terms of neuroexcitotoxicity QZZG inhibited glutamate content, reduced Ca2+ inward flow, protected mitochondrial function, and reduced ROS, as well as being able to effectively inhibit the expression of NMDAR1, Caspase-3, Bax, and promote the expression of Bcl-2, NMDAR2A. In terms of ferroptosis QZZG promoted NRF2, HO-1, GPX4 and nuclear-NRF2, inhibited the expression of BACH1 and ACSL4, and suppressed Fe2+ accumulation and lipid peroxidation. Silencing of BACH1 resulted in elevated expression of NRF2 and decreased expression of ACSL4, which inhibited the sensitivity of neurons to ferroptosis. QZZG was able to further increase NRF2 expression under conditions of silencing BACH1. QZZG induced NRF2 and inhibited BACH1, ACSL4 was inhibited by ML385, and inhibition of NRF2 induced the expression of BACH1 and ACSL4, QZZG protects neurons in an NRF2-dependent manner. In summary, QZZG inhibited neuroexcitotoxicity and ferroptosis by regulating the NMDAR/NRF2/BACH1/ACSL4 pathway. The study provided a relatively novel perspective on the mechanism of traditional Chinese medicine (TCM) treatment of the disease. [Display omitted] •Silencing BACH1 attenuated ACSL4 expression and resulted in attenuation of neuronal sensitivity to ferroptosis.•QZZG inhibited neuroexcitotoxicity and ferroptosis through NMDAR/NRF2/BACH1/ACSL4 pathway.•Inhibition of NRF2 attenuated the protective effect of QZZG on neurons.
doi_str_mv 10.1016/j.freeradbiomed.2024.12.029
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3146848656</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0891584924011389</els_id><sourcerecordid>3146848656</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1702-72e72ee1eaa7ca38ab3f26aeca6aeef0e6e831d5ea94949d4a299b3c36fbc4183</originalsourceid><addsrcrecordid>eNqNkctu1DAUhi1ERaeFV0CR2LBxxrfcxGqY3pCGFhVYW45z0njIxMF2aGfXh-BJ-iA8BE9Sj6ZdsEO2fBb-zn9sfQi9oySlhObzddo6AKea2tgNNCkjTKSUpYRVL9CMlgXHIqvyl2hGyorirBTVITryfk0IERkvX6FDXuVFlnE2Q7-_GA0qqGGwPeZ_7x_wFf7zgE_wTT9pO26dGqw3DSRm6Extgk8GmJyFO22CDfbOxLpN1NAkLThnxxBpn4TO2emmSy4_nyyu55fXZ2z-cbG8oPPF8utKJKMK3a3axsxE6SnEcK872Bid-ODsD3iNDlrVe3jzVI_R97PTb8sLvLo6_7RcrLCmBWG4YBA3UFCq0IqXquYtyxVoFQ9oCeRQctpkoCoRVyMUq6qaa563tRa05Mfo_T53dPbnBD7ITXwJ9L0awE5eciryUpR5lkf0wx7VznrvoJWjMxvltpISudMi1_IfLXKnRVImo5bY_fZp0FTv7p57nz1E4HQPQPzuLwNOem1g0NAYBzrIxpr_GvQIEcuqhA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3146848656</pqid></control><display><type>article</type><title>Piceatannol-3′-O-β-D-glucopyranoside inhibits neuroexcitotoxicity and ferroptosis through NMDAR/NRF2/BACH1/ACSL4 pathway in acute ischemic stroke</title><source>Elsevier ScienceDirect Journals</source><creator>Fan, Genhao ; Liu, Jia ; Liu, Menglin ; Huang, Yuhong</creator><creatorcontrib>Fan, Genhao ; Liu, Jia ; Liu, Menglin ; Huang, Yuhong</creatorcontrib><description>Neuronal protection is a well-established method of acute ischemic stroke (AIS) treatment. The pharmacodynamic effect of Piceatannol-3′-O-β-D-glucopyranoside (Chinese name: Hartigan, QZZG) on AIS has been reported, but the molecular mechanism of this effect remains unknown. The purpose of this study is to elucidate the pharmacodynamic effects and mechanisms of QZZG in the treatment of AIS. A combined network pharmacology and metabolomics approach was used to predict the key targets and pathways of QZZG in the treatment of AIS and to elucidate the mechanism of QZZG through experimental validation. In this study, QZZG improved histopathologic features and reduced infarct volume and neurologic deficit scores. Integrated network pharmacology and metabolomics revealed that QZZG may protect neurons by regulating glutamate and its receptors, and that glutamate is closely related to NMDAR1, NRF2, and Caspase-3. Pathway analysis results suggested that NMDAR-mediated Ca2+ inward flow is one of the critical pathways. In terms of neuroexcitotoxicity QZZG inhibited glutamate content, reduced Ca2+ inward flow, protected mitochondrial function, and reduced ROS, as well as being able to effectively inhibit the expression of NMDAR1, Caspase-3, Bax, and promote the expression of Bcl-2, NMDAR2A. In terms of ferroptosis QZZG promoted NRF2, HO-1, GPX4 and nuclear-NRF2, inhibited the expression of BACH1 and ACSL4, and suppressed Fe2+ accumulation and lipid peroxidation. Silencing of BACH1 resulted in elevated expression of NRF2 and decreased expression of ACSL4, which inhibited the sensitivity of neurons to ferroptosis. QZZG was able to further increase NRF2 expression under conditions of silencing BACH1. QZZG induced NRF2 and inhibited BACH1, ACSL4 was inhibited by ML385, and inhibition of NRF2 induced the expression of BACH1 and ACSL4, QZZG protects neurons in an NRF2-dependent manner. In summary, QZZG inhibited neuroexcitotoxicity and ferroptosis by regulating the NMDAR/NRF2/BACH1/ACSL4 pathway. The study provided a relatively novel perspective on the mechanism of traditional Chinese medicine (TCM) treatment of the disease. [Display omitted] •Silencing BACH1 attenuated ACSL4 expression and resulted in attenuation of neuronal sensitivity to ferroptosis.•QZZG inhibited neuroexcitotoxicity and ferroptosis through NMDAR/NRF2/BACH1/ACSL4 pathway.•Inhibition of NRF2 attenuated the protective effect of QZZG on neurons.</description><identifier>ISSN: 0891-5849</identifier><identifier>ISSN: 1873-4596</identifier><identifier>EISSN: 1873-4596</identifier><identifier>DOI: 10.1016/j.freeradbiomed.2024.12.029</identifier><identifier>PMID: 39675532</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Acute ischemic stroke ; Ferroptosis ; Metabolomics ; Network pharmacology ; Neuroexcitotoxicity ; Piceatannol-3′-O-β-D-glucopyranoside</subject><ispartof>Free radical biology &amp; medicine, 2025-02, Vol.227, p.667-679</ispartof><rights>2024 Elsevier Inc.</rights><rights>Copyright © 2024 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1702-72e72ee1eaa7ca38ab3f26aeca6aeef0e6e831d5ea94949d4a299b3c36fbc4183</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0891584924011389$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27902,27903,65308</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39675532$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fan, Genhao</creatorcontrib><creatorcontrib>Liu, Jia</creatorcontrib><creatorcontrib>Liu, Menglin</creatorcontrib><creatorcontrib>Huang, Yuhong</creatorcontrib><title>Piceatannol-3′-O-β-D-glucopyranoside inhibits neuroexcitotoxicity and ferroptosis through NMDAR/NRF2/BACH1/ACSL4 pathway in acute ischemic stroke</title><title>Free radical biology &amp; medicine</title><addtitle>Free Radic Biol Med</addtitle><description>Neuronal protection is a well-established method of acute ischemic stroke (AIS) treatment. The pharmacodynamic effect of Piceatannol-3′-O-β-D-glucopyranoside (Chinese name: Hartigan, QZZG) on AIS has been reported, but the molecular mechanism of this effect remains unknown. The purpose of this study is to elucidate the pharmacodynamic effects and mechanisms of QZZG in the treatment of AIS. A combined network pharmacology and metabolomics approach was used to predict the key targets and pathways of QZZG in the treatment of AIS and to elucidate the mechanism of QZZG through experimental validation. In this study, QZZG improved histopathologic features and reduced infarct volume and neurologic deficit scores. Integrated network pharmacology and metabolomics revealed that QZZG may protect neurons by regulating glutamate and its receptors, and that glutamate is closely related to NMDAR1, NRF2, and Caspase-3. Pathway analysis results suggested that NMDAR-mediated Ca2+ inward flow is one of the critical pathways. In terms of neuroexcitotoxicity QZZG inhibited glutamate content, reduced Ca2+ inward flow, protected mitochondrial function, and reduced ROS, as well as being able to effectively inhibit the expression of NMDAR1, Caspase-3, Bax, and promote the expression of Bcl-2, NMDAR2A. In terms of ferroptosis QZZG promoted NRF2, HO-1, GPX4 and nuclear-NRF2, inhibited the expression of BACH1 and ACSL4, and suppressed Fe2+ accumulation and lipid peroxidation. Silencing of BACH1 resulted in elevated expression of NRF2 and decreased expression of ACSL4, which inhibited the sensitivity of neurons to ferroptosis. QZZG was able to further increase NRF2 expression under conditions of silencing BACH1. QZZG induced NRF2 and inhibited BACH1, ACSL4 was inhibited by ML385, and inhibition of NRF2 induced the expression of BACH1 and ACSL4, QZZG protects neurons in an NRF2-dependent manner. In summary, QZZG inhibited neuroexcitotoxicity and ferroptosis by regulating the NMDAR/NRF2/BACH1/ACSL4 pathway. The study provided a relatively novel perspective on the mechanism of traditional Chinese medicine (TCM) treatment of the disease. [Display omitted] •Silencing BACH1 attenuated ACSL4 expression and resulted in attenuation of neuronal sensitivity to ferroptosis.•QZZG inhibited neuroexcitotoxicity and ferroptosis through NMDAR/NRF2/BACH1/ACSL4 pathway.•Inhibition of NRF2 attenuated the protective effect of QZZG on neurons.</description><subject>Acute ischemic stroke</subject><subject>Ferroptosis</subject><subject>Metabolomics</subject><subject>Network pharmacology</subject><subject>Neuroexcitotoxicity</subject><subject>Piceatannol-3′-O-β-D-glucopyranoside</subject><issn>0891-5849</issn><issn>1873-4596</issn><issn>1873-4596</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><recordid>eNqNkctu1DAUhi1ERaeFV0CR2LBxxrfcxGqY3pCGFhVYW45z0njIxMF2aGfXh-BJ-iA8BE9Sj6ZdsEO2fBb-zn9sfQi9oySlhObzddo6AKea2tgNNCkjTKSUpYRVL9CMlgXHIqvyl2hGyorirBTVITryfk0IERkvX6FDXuVFlnE2Q7-_GA0qqGGwPeZ_7x_wFf7zgE_wTT9pO26dGqw3DSRm6Extgk8GmJyFO22CDfbOxLpN1NAkLThnxxBpn4TO2emmSy4_nyyu55fXZ2z-cbG8oPPF8utKJKMK3a3axsxE6SnEcK872Bid-ODsD3iNDlrVe3jzVI_R97PTb8sLvLo6_7RcrLCmBWG4YBA3UFCq0IqXquYtyxVoFQ9oCeRQctpkoCoRVyMUq6qaa563tRa05Mfo_T53dPbnBD7ITXwJ9L0awE5eciryUpR5lkf0wx7VznrvoJWjMxvltpISudMi1_IfLXKnRVImo5bY_fZp0FTv7p57nz1E4HQPQPzuLwNOem1g0NAYBzrIxpr_GvQIEcuqhA</recordid><startdate>20250201</startdate><enddate>20250201</enddate><creator>Fan, Genhao</creator><creator>Liu, Jia</creator><creator>Liu, Menglin</creator><creator>Huang, Yuhong</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20250201</creationdate><title>Piceatannol-3′-O-β-D-glucopyranoside inhibits neuroexcitotoxicity and ferroptosis through NMDAR/NRF2/BACH1/ACSL4 pathway in acute ischemic stroke</title><author>Fan, Genhao ; Liu, Jia ; Liu, Menglin ; Huang, Yuhong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1702-72e72ee1eaa7ca38ab3f26aeca6aeef0e6e831d5ea94949d4a299b3c36fbc4183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Acute ischemic stroke</topic><topic>Ferroptosis</topic><topic>Metabolomics</topic><topic>Network pharmacology</topic><topic>Neuroexcitotoxicity</topic><topic>Piceatannol-3′-O-β-D-glucopyranoside</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fan, Genhao</creatorcontrib><creatorcontrib>Liu, Jia</creatorcontrib><creatorcontrib>Liu, Menglin</creatorcontrib><creatorcontrib>Huang, Yuhong</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Free radical biology &amp; medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fan, Genhao</au><au>Liu, Jia</au><au>Liu, Menglin</au><au>Huang, Yuhong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Piceatannol-3′-O-β-D-glucopyranoside inhibits neuroexcitotoxicity and ferroptosis through NMDAR/NRF2/BACH1/ACSL4 pathway in acute ischemic stroke</atitle><jtitle>Free radical biology &amp; medicine</jtitle><addtitle>Free Radic Biol Med</addtitle><date>2025-02-01</date><risdate>2025</risdate><volume>227</volume><spage>667</spage><epage>679</epage><pages>667-679</pages><issn>0891-5849</issn><issn>1873-4596</issn><eissn>1873-4596</eissn><abstract>Neuronal protection is a well-established method of acute ischemic stroke (AIS) treatment. The pharmacodynamic effect of Piceatannol-3′-O-β-D-glucopyranoside (Chinese name: Hartigan, QZZG) on AIS has been reported, but the molecular mechanism of this effect remains unknown. The purpose of this study is to elucidate the pharmacodynamic effects and mechanisms of QZZG in the treatment of AIS. A combined network pharmacology and metabolomics approach was used to predict the key targets and pathways of QZZG in the treatment of AIS and to elucidate the mechanism of QZZG through experimental validation. In this study, QZZG improved histopathologic features and reduced infarct volume and neurologic deficit scores. Integrated network pharmacology and metabolomics revealed that QZZG may protect neurons by regulating glutamate and its receptors, and that glutamate is closely related to NMDAR1, NRF2, and Caspase-3. Pathway analysis results suggested that NMDAR-mediated Ca2+ inward flow is one of the critical pathways. In terms of neuroexcitotoxicity QZZG inhibited glutamate content, reduced Ca2+ inward flow, protected mitochondrial function, and reduced ROS, as well as being able to effectively inhibit the expression of NMDAR1, Caspase-3, Bax, and promote the expression of Bcl-2, NMDAR2A. In terms of ferroptosis QZZG promoted NRF2, HO-1, GPX4 and nuclear-NRF2, inhibited the expression of BACH1 and ACSL4, and suppressed Fe2+ accumulation and lipid peroxidation. Silencing of BACH1 resulted in elevated expression of NRF2 and decreased expression of ACSL4, which inhibited the sensitivity of neurons to ferroptosis. QZZG was able to further increase NRF2 expression under conditions of silencing BACH1. QZZG induced NRF2 and inhibited BACH1, ACSL4 was inhibited by ML385, and inhibition of NRF2 induced the expression of BACH1 and ACSL4, QZZG protects neurons in an NRF2-dependent manner. In summary, QZZG inhibited neuroexcitotoxicity and ferroptosis by regulating the NMDAR/NRF2/BACH1/ACSL4 pathway. The study provided a relatively novel perspective on the mechanism of traditional Chinese medicine (TCM) treatment of the disease. [Display omitted] •Silencing BACH1 attenuated ACSL4 expression and resulted in attenuation of neuronal sensitivity to ferroptosis.•QZZG inhibited neuroexcitotoxicity and ferroptosis through NMDAR/NRF2/BACH1/ACSL4 pathway.•Inhibition of NRF2 attenuated the protective effect of QZZG on neurons.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>39675532</pmid><doi>10.1016/j.freeradbiomed.2024.12.029</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0891-5849
ispartof Free radical biology & medicine, 2025-02, Vol.227, p.667-679
issn 0891-5849
1873-4596
1873-4596
language eng
recordid cdi_proquest_miscellaneous_3146848656
source Elsevier ScienceDirect Journals
subjects Acute ischemic stroke
Ferroptosis
Metabolomics
Network pharmacology
Neuroexcitotoxicity
Piceatannol-3′-O-β-D-glucopyranoside
title Piceatannol-3′-O-β-D-glucopyranoside inhibits neuroexcitotoxicity and ferroptosis through NMDAR/NRF2/BACH1/ACSL4 pathway in acute ischemic stroke
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T09%3A39%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Piceatannol-3%E2%80%B2-O-%CE%B2-D-glucopyranoside%20inhibits%20neuroexcitotoxicity%20and%20ferroptosis%20through%20NMDAR/NRF2/BACH1/ACSL4%20pathway%20in%20acute%20ischemic%20stroke&rft.jtitle=Free%20radical%20biology%20&%20medicine&rft.au=Fan,%20Genhao&rft.date=2025-02-01&rft.volume=227&rft.spage=667&rft.epage=679&rft.pages=667-679&rft.issn=0891-5849&rft.eissn=1873-4596&rft_id=info:doi/10.1016/j.freeradbiomed.2024.12.029&rft_dat=%3Cproquest_cross%3E3146848656%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3146848656&rft_id=info:pmid/39675532&rft_els_id=S0891584924011389&rfr_iscdi=true